Phase II trial of sorafenib as second line therapy in patients with advanced or metastatic gastric cancer.

Trial Profile

Phase II trial of sorafenib as second line therapy in patients with advanced or metastatic gastric cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2009

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Jul 2009 Actual patient number (5) added as reported by ClinicalTrials.gov.
    • 22 May 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 01 Feb 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top